Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
暂无分享,去创建一个
I. Bruce | D. Gladman | E. Ginzler | C. Gordon | J. Hanly | D. Isenberg | K. Kalunian | O. Nived | M. Petri | J. Sánchez-Guerrero | M. Urowitz | G. Sturfelt | J. Buyon | S. Bernatsky | K. Steinsson | M. Khamashta | D. Wallace | G. Ruiz-Irastorza | R. Cervera | D. Kamen | M. Inanç | J. Merrill | S. Manzi | R. Ramsey‐Goldman | D. Kamen | P. Fortin | C. Peschken | J. Hanly | M. Khamashta | A. Zoma | S. Jacobsen | J. Sturgess | C. Aranow | J. Romero-Diaz | E. Ginzler | D. Gladman | M. Dooley | A. Rahman | A. Clarke | S. Lim | R. van Vollenhoven | A. Askanase | S. Bernatsky | A. Zoma | E. Allen | B. Sang-Cheol | A. Clarke | I. Bruce | J. Romero-Díaz | P. Fortin | S. Lim | G. Ruiz‐Irastorza | Daniel J. Wallace | R. V. Vollenhoven
[1] A. Orbai,et al. Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary , 2015, The Journal of Rheumatology.
[2] E. Chakravarty,et al. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. , 2014, Rheumatology.
[3] C. Gordon,et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) , 2014, Annals of the rheumatic diseases.
[4] D. Isenberg,et al. Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects. , 2013, Best practice & research. Clinical rheumatology.
[5] M. Petri,et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.
[6] Gerald McGwin,et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.
[7] M. Urowitz,et al. International consensus for a definition of disease flare in lupus , 2011, Lupus.
[8] I. Bruce,et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA , 2010, Annals of the rheumatic diseases.
[9] I. Bruce,et al. Numerical scoring for the BILAG-2004 index , 2010, Rheumatology.
[10] I. Bruce,et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients , 2010, Rheumatology.
[11] I. Bruce,et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity , 2009, Rheumatology.
[12] Mimi Y. Kim,et al. Outcomes of planned home births with certified professional midwives: large prospective study in North America , 2005, BMJ : British Medical Journal.
[13] C. Gordon,et al. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. , 2004, The Journal of rheumatology.
[14] D. Gladman,et al. Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.
[15] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[16] C. Gordon,et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.